[go: up one dir, main page]

AU2002239282A1 - Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof - Google Patents

Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof

Info

Publication number
AU2002239282A1
AU2002239282A1 AU2002239282A AU3928202A AU2002239282A1 AU 2002239282 A1 AU2002239282 A1 AU 2002239282A1 AU 2002239282 A AU2002239282 A AU 2002239282A AU 3928202 A AU3928202 A AU 3928202A AU 2002239282 A1 AU2002239282 A1 AU 2002239282A1
Authority
AU
Australia
Prior art keywords
paclitaxel
derivatives
pharmaceutically acceptable
acceptable salts
pharmaceutical formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002239282A
Inventor
Hongming Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transform Pharmaceuticals Inc
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Publication of AU2002239282A1 publication Critical patent/AU2002239282A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002239282A 2000-11-28 2001-11-20 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof Abandoned AU2002239282A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25364000P 2000-11-28 2000-11-28
US60/253,640 2000-11-28
US27211701P 2001-02-28 2001-02-28
US60/272,117 2001-02-28
PCT/US2001/043306 WO2002043765A2 (en) 2000-11-28 2001-11-20 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof

Publications (1)

Publication Number Publication Date
AU2002239282A1 true AU2002239282A1 (en) 2002-06-11

Family

ID=26943439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002239282A Abandoned AU2002239282A1 (en) 2000-11-28 2001-11-20 Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof

Country Status (5)

Country Link
US (2) US6919370B2 (en)
EP (1) EP1337273A2 (en)
JP (1) JP2004536026A (en)
AU (1) AU2002239282A1 (en)
WO (1) WO2002043765A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919370B2 (en) 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
IN188917B (en) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
JP2004520398A (en) * 2001-01-18 2004-07-08 ファルマシア・アンド・アップジョン・カンパニー Paclitaxel chemotherapy microemulsion composition with improved oral bioavailability
US20030003144A1 (en) * 2001-05-01 2003-01-02 Keller Brian C. Sustained release formulations for nifedipine, dextromethorphan, and danazol
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
RS52904A (en) * 2001-12-20 2006-12-15 Bristol-Myers Squib Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
KR100573289B1 (en) * 2002-07-20 2006-04-24 대화제약 주식회사 Paclitaxel composition for the treatment of bladder cancer through intra-bladder administration and method for preparing the same
WO2004050068A1 (en) * 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
SI1583562T1 (en) 2003-01-06 2011-10-28 Angiochem Inc Angiopep-1, related compounds, and uses thereof
CA2521221A1 (en) * 2003-04-02 2004-10-14 Genix Therapeutics, Inc. Method for the treatment of prostate cancer
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
ATE427943T1 (en) * 2003-12-12 2009-04-15 Quiral Quimica Do Brasil METHOD FOR PRODUCING ANHYDROUS AND HYDRATED PHARMACEUTICAL ACTIVE INGREDIENTS (APIS); STABLE PHARMACEUTICAL COMPOSITIONS PRODUCED FROM THESE AND USES FOR THESE COMPOSITIONS
WO2005074889A1 (en) * 2004-02-03 2005-08-18 Dinesh Shantilal Patel Novel compositions of taxol derivatives and the process for the manufacture thereof
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US7659310B2 (en) 2004-04-27 2010-02-09 Formatech, Inc. Methods of enhancing solubility of agents
CA2580202A1 (en) * 2004-09-13 2006-03-23 Bharat Serums & Vaccines Ltd. Stable emulsion compositions for intravenous administration having antimicrobial preservative efficacy
JP2008543789A (en) * 2005-06-17 2008-12-04 ホスピラ オーストラリア ピーティーワイ エルティーディー Docetaxel liquid pharmaceutical formulation
DK2433653T3 (en) 2005-07-15 2019-08-19 Angiochem Inc Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
DE602006004887D1 (en) * 2005-08-05 2009-03-05 Bharat Serums & Vaccines Ltd INTRAVENOUS PROPOFOL EMULSION COMPOSITIONS WITH CONSERVATIVE EFFECT
WO2007052295A2 (en) * 2005-08-12 2007-05-10 Bharat Serums & Vaccines Ltd. Aqueous anaesthetic compositions comprising propofol
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
CA2620389C (en) * 2005-08-31 2014-06-17 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
PL3311805T3 (en) * 2005-08-31 2020-07-27 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
AR054215A1 (en) 2006-01-20 2007-06-13 Eriochem Sa A PHARMACEUTICAL FORMULATION OF A TAXANE, A SOLID COMPOSITION OF A LIOFILIZED TAXAN FROM AN ACETIC ACID SOLUTION, A PROCEDURE FOR THE PREPARATION OF A SOLID COMPOSITION OF A TAXANE, A SOLUBILIZING COMPOSITION OF A LIOFILIZED TAXANE AND AN ELEMENTARY KIT
CN101023940A (en) * 2006-02-20 2007-08-29 郝守祝 Medicine composition of Taxane compounds, preparing method and use
WO2007134354A1 (en) * 2006-05-23 2007-11-29 Ebewe Pharma Ges.M.B.H. Nfg. Kg Pharmaceutical formulation
EP2092942A1 (en) * 2006-11-20 2009-08-26 Lutonix, Inc. Drug releasing coatings for medical devices
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
EP1946747A1 (en) * 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
EP2205215A2 (en) * 2007-10-01 2010-07-14 Intas Pharmaceuticals Limited Docetaxel injectable composition, being absolutely free of ethanol
AR063111A1 (en) 2007-10-03 2008-12-30 Eriochem Sa A PHARMACEUTICAL FORMULATION OF TAXANO
KR101053780B1 (en) * 2008-02-29 2011-08-02 동아제약주식회사 Single liquid stable pharmaceutical composition containing docetaxel
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
WO2009127072A1 (en) * 2008-04-18 2009-10-22 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
WO2010023321A1 (en) * 2008-09-01 2010-03-04 Stragen Pharma S.A. Liquid formulation containing a taxane derivative
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
US20110195030A1 (en) * 2008-10-15 2011-08-11 The University Of North Carolina At Chapel Hill Nanoparticle compositions comprising liquid oil cores
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
CN102300987A (en) 2008-12-17 2011-12-28 安吉奥开米公司 Membrane Type-1 Matrix Metalloprotein Inhibitors And Uses Thereof
ES2729261T3 (en) 2009-04-20 2019-10-31 Angiochem Inc Ovarian cancer treatment using an anticancer agent conjugated to an Angiopep-2 analog
RU2012103240A (en) 2009-07-02 2013-08-10 Ангиокем Инк. MULTI-DIMENSIONAL PEPTIDE CONJUGATES AND THEIR APPLICATION
CA2781527C (en) 2009-09-23 2017-10-24 Indu Javeri Methods for the preparation of liposomes
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
US20120065255A1 (en) * 2009-10-19 2012-03-15 Nagesh Palepu Cabazitaxel formulations and methods of preparing thereof
BR112012015369A2 (en) * 2009-12-23 2018-01-23 Piramal Imaging Sa formulations suitable for pet imaging with hydrophobic pet agents
AU2011248449B2 (en) * 2010-05-03 2016-09-15 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2012021791A2 (en) * 2010-08-13 2012-02-16 Scidose Llc Aqueous formulation with improved stability
JP5868414B2 (en) 2010-11-08 2016-02-24 カディラ ファーマシューティカルズ リミテッド Taxoid pharmaceutical composition
JP6038921B2 (en) 2011-08-30 2016-12-07 アステックス ファーマシューティカルズ インコーポレイテッド Decitabine derivative preparation
AU2013359048A1 (en) * 2012-12-13 2015-07-02 Cytrx Corporation Anthracycline formulations
CA2989400A1 (en) 2015-06-15 2016-12-22 Angiochem Inc. Ang1005 for the treatment of leptomeningeal carcinomatosis
JP7340863B2 (en) * 2018-06-29 2023-09-08 学校法人同志社 Preparations containing emricasan

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US505047A (en) * 1893-09-12 Pump-curb
US522936A (en) * 1894-07-10 of philadelphia
US295941A (en) * 1884-04-01 Daniel alison eadley
US428376A (en) * 1890-05-20 Clutch mechanism
US522937A (en) * 1894-07-10 Angus fougere
US667142A (en) * 1900-03-13 1901-01-29 Max Sarfert Process of treating hosiery.
US674510A (en) * 1900-07-16 1901-05-21 John Monh Combined tap and pump.
US694178A (en) * 1901-12-30 1902-02-25 John W Norman Nut-lock.
US1235452A (en) * 1915-04-23 1917-07-31 Nye Odorless Crematory Company Crematory.
US1440275A (en) * 1921-08-05 1922-12-26 Saul Yavitz Angle-indicating level and plumb
DE694178C (en) 1930-11-30 1940-07-27 I G Farbenindustrie Akt Ges Process for the preparation of condensation products which are soluble or easily dispersible in water
NL268805A (en) 1960-09-02
US3070499A (en) * 1960-09-19 1962-12-25 Merck & Co Inc Parenteral aqueous solutions of fat soluble vitamins
US3220923A (en) * 1961-10-31 1965-11-30 Bayer Ag Aqueous injectable compositions and methods for effecting narcosis
DE1235452B (en) 1964-08-19 1967-03-02 Kernforschung Gmbh Ges Fuer Steam-cooled nuclear reactor
DE1901535A1 (en) * 1969-01-14 1970-08-13 Henkel & Cie Gmbh Process for the preparation of alkylene glycol esters
JPS552421B2 (en) * 1971-08-06 1980-01-19
DE2911241A1 (en) 1979-03-22 1980-10-02 Basf Ag ALCOXYLATED FATTY ACIDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS SOLUTION MEDIATOR
US4366370A (en) * 1980-02-12 1982-12-28 Moore James L Motor/generator armature portable baking oven
US4572915A (en) * 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
FR2601675B1 (en) * 1986-07-17 1988-09-23 Rhone Poulenc Sante TAXOL DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IE59934B1 (en) 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
MX9203804A (en) * 1987-10-19 1992-07-01 Liposome Co Inc PHARMACEUTICAL SYSTEMS BASED ON TOCOPHEROL.
US5157049A (en) * 1988-03-07 1992-10-20 The United States Of America As Represented By The Department Of Health & Human Services Method of treating cancers sensitive to treatment with water soluble derivatives of taxol
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
AU5157590A (en) 1989-02-06 1990-08-24 Abbott Laboratories Pharmaceutical compositions for oral administration
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5136060A (en) 1989-11-14 1992-08-04 Florida State University Method for preparation of taxol using an oxazinone
FR2657526B1 (en) * 1990-01-31 1994-10-28 Lvmh Rech USE OF AN ALPHA-TOCOPHEROL PHOSPHATE, OR ONE OF ITS DERIVATIVES, FOR THE PREPARATION OF COSMETIC, DERMATOLOGICAL, OR PHARMACEUTICAL COMPOSITIONS; COMPOSITIONS THUS OBTAINED.
EP0468044B1 (en) * 1990-02-15 1995-10-11 PQ Corporation Method of frying oil treatment using an alumina and amorphous silica composition
TW223634B (en) 1991-03-18 1994-05-11 Kingston David G I
US5698582A (en) * 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
FR2678833B1 (en) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa NEW PHARMACEUTICAL COMPOSITIONS BASED ON DERIVATIVES OF THE TAXANE CLASS.
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5281727A (en) * 1992-11-27 1994-01-25 Napro Biotherapeutics, Inc. Method of using ion exchange media to increase taxane yields
ES2119996T3 (en) 1992-11-27 1998-10-16 Napro Biotherapeutics Inc INJECTABLE COMPOSITION INCLUDING FACLITAXEL.
KR100371062B1 (en) 1992-11-27 2003-04-21 에프.에이치.포울딩 앤드 컴퍼니 리미티드 Injectable taxi brush compositions with improved stability and methods of formulating them
FR2698543B1 (en) * 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa New taxoid-based compositions.
EP0632333B2 (en) * 1993-06-29 2003-10-01 Hewlett-Packard Company, A Delaware Corporation Cross-linked polyvinyl butyral binder for organic photoconductor
TW406020B (en) * 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
DE69535127T2 (en) * 1994-03-18 2007-02-15 Supernus Pharmaceuticals, Inc. EMULSIFIED DRUG DISPENSING SYSTEMS
US5681846A (en) * 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
WO1997023208A1 (en) * 1995-12-21 1997-07-03 Genelabs Technologies, Inc. Taxane composition and method
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US5877205A (en) * 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
DE69716485T2 (en) * 1997-05-30 2003-04-10 Man Woo Han TAXOL CONTAINING PHARMACEUTICAL INJECTION SOLUTION
CA2211949A1 (en) * 1997-07-21 1999-01-29 David Farley Johnson Nonaqueous compositions for parenteral administration
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
KR19990075621A (en) * 1998-03-23 1999-10-15 임성주 Inclined Plate Culture Tank
WO1999049848A1 (en) 1998-04-01 1999-10-07 Rtp Pharma Inc. Anticancer compositions
CN1273526A (en) 1998-07-14 2000-11-15 Em工业股份有限公司 Microdisperse drug delivery systems
US6040330A (en) 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
MXPA01011981A (en) 1999-05-24 2003-09-04 Sonus Pharma Inc Emulsion vehicle for poorly soluble drugs.
WO2001022937A1 (en) 1999-09-27 2001-04-05 Sonus Pharmaceuticals, Inc. Compositions of tocol-soluble therapeutics
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
CN1450923A (en) 1999-10-27 2003-10-22 巴克·诺顿药物有限公司 Method and compositions for administering taxanes orally to human patients
US6919370B2 (en) 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof

Also Published As

Publication number Publication date
WO2002043765A9 (en) 2003-02-13
JP2004536026A (en) 2004-12-02
US20030207936A1 (en) 2003-11-06
WO2002043765A2 (en) 2002-06-06
US20050191323A1 (en) 2005-09-01
WO2002043765A3 (en) 2002-11-21
US6919370B2 (en) 2005-07-19
EP1337273A2 (en) 2003-08-27

Similar Documents

Publication Publication Date Title
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
HUP0203312A3 (en) Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
AU2001237526A1 (en) Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof
AU2002239397A1 (en) Drug formulation having improved oral tolerability
HUP0303891A3 (en) Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them
AU2001237525A1 (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
AU2001282267A1 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
AU2682401A (en) Flavonoid drug and dosage form, its production and use
AU2001262221A1 (en) Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
AU2001266338A1 (en) Pharmaceutical compositions for angiogenic therapy
IL159217A0 (en) An oral pharmaceutical formulation comprising a basic pharmaceutically active ingredient having ph-dependent solubility, a process for the manufacture thereof and use thereof in medicine
ZA200308221B (en) Pharmaceutical compositions for oral and topical administration.
HRPK20010706B1 (en) Tolperison-containing, pharmaceutical preparation for oral administration
AU2001284444A1 (en) Preparations for oral administration
AU2001245316A1 (en) Naphtalene derivatives and their pharmaceutical use
AU6715600A (en) Pharmaceutical formulations
AU2001292331A2 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2001292331A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
IL154240A0 (en) 4-pyrimidinamine derivatives, pharmaceutical compositions and related methods
AU2001228810A1 (en) Benzene-fused heterocycle derivatives and drugs containing the same as the active ingredient
AU4977300A (en) Pharmaceutical formulations
AU2002346457A1 (en) Pharmaceutical formulations comprising indolinone derivatives